Dr Reddy Laboratories (RDY) Weak On High Volume
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Dr Reddy Laboratories as such a stock due to the following factors:
- RDY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $31.8 million.
- RDY has traded 131,744 shares today.
- RDY is trading at 4.28 times the normal volume for the stock at this time of day.
- RDY is trading at a new low 7.05% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RDY with the Ticky from Trade-Ideas. See the FREE profile for RDY NOW at Trade-Ideas
More details on RDY:
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The stock currently has a dividend yield of 0.6%. RDY has a PE ratio of 25. Currently there are no analysts that rate Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.
The average volume for Dr Reddy Laboratories has been 440,600 shares per day over the past 30 days. Dr Reddy has a market cap of $9.1 billion and is part of the health care sector and drugs industry. Shares are up 4.7% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Dr Reddy Laboratories as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 7.1%. Since the same quarter one year prior, revenues slightly increased by 8.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The current debt-to-equity ratio, 0.31, is low and is below the industry average, implying that there has been successful management of debt levels.
- The stock has not only risen over the past year, it has done so at a faster pace than the S&P 500, reflecting the earnings growth and other positive factors similar to those we have cited here. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- The gross profit margin for DR REDDY'S LABORATORIES LTD is rather high; currently it is at 61.34%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, RDY's net profit margin of 18.09% significantly trails the industry average.
- DR REDDY'S LABORATORIES LTD has improved earnings per share by 23.1% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, DR REDDY'S LABORATORIES LTD reported lower earnings of $2.07 versus $2.10 in the prior year. This year, the market expects an improvement in earnings ($2.54 versus $2.07).
- You can view the full Dr Reddy Laboratories Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.